Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers (Q43179682)

15 November 2017

Autologus dendritic cell vaccine for chronic hepatitis B carriers: a pilot, open label, clinical trial in human volunteers (English)

1 reference

15 November 2017

1 reference

1 reference

1 reference

Jin Luo

1

1 reference

15 November 2017

Jun Li

2

1 reference

15 November 2017

Rui L Chen

3

1 reference

15 November 2017

Lei Nie

4

1 reference

15 November 2017

Jie Huang

5

1 reference

15 November 2017

Zheng W Liu

6

1 reference

15 November 2017

Lin Luo

7

1 reference

15 November 2017

Xiao J Yan

8

1 reference

15 November 2017

language of work or name

English

0 references

publication date

29 January 2010

1 reference

15 November 2017

1 reference

15 November 2017

28

1 reference

15 November 2017

13

1 reference

15 November 2017

2497-2504

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

15 November 2017

1 reference

The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

The treatment of chronic viral hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

The dendritic cell system and its role in immunogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Dendritic cells and chronic hepatitis virus carriers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Production of antibody to hepatitis B surface antigen (anti-HBs) by murine hepatitis B virus carriers: neonatal tolerance versus antigen presentation by dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted T cells in situ

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Recent advances in the study of dendritic cells and follicular dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Therapeutic dendritic-cell vaccine for simian AIDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

A transgenic mouse model of the chronic hepatitis B surface antigen carrier state

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Safety and efficacy of hepatitis B surface antigen-pulsed dendritic cells in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Hepatitis B virus core antigen epitopes presented by HLA-A2 single-chain trimers induce functional epitope-specific CD8+ T-cell responses in HLA-A2.1/Kb transgenic mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Therapeutic dendritic-cell vaccine for chronic HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Rapid and high throughput detection of HBV YMDD mutants with fluorescence polarization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Long-term safety of lamivudine treatment in patients with chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Management of patients with HBeAg-negative chronic hepatitis B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.01.038

10.1016/J.VACCINE.2010.01.038

7 January 2021

Identifiers

DOI

1 reference

15 November 2017

1 reference